InMode's Resilience Amidst Challenges: A Buy Rating With a Positive Outlook on Upcoming Product Launches and Market Recovery
Needham Maintains InMode(INMD.US) With Hold Rating
InMode's Hold Rating Amid Decelerating Growth and Economic Headwinds
Jefferies Cuts Inmode to Hold, Cites Macro Pressures
InMode Analyst Ratings
Jefferies Downgrades InMode to Hold, Lowers Price Target to $19
Jefferies Downgrades InMode(INMD.US) to Hold Rating, Cuts Target Price to $19
InMode's Business Outlook: Maintaining a Hold Rating Amid Market Challenges and Lowered Forecasts
Barclays Lowers Price Target on InMode to $29 From $33, Maintains Overweight Rating
Barclays Maintains Overweight on InMode, Lowers Price Target to $29
InMode Analyst Ratings
Analysts Offer Insights on Healthcare Companies: InMode (INMD), Fortrea Holdings Inc. (FTRE) and Lexeo Therapeutics, Inc. (LXEO)
Maintaining a Buy Rating: InMode's Resilience Amidst Aesthetic Procedure Slowdown and Strategic Growth Prospects
Canaccord Genuity Maintains Hold on InMode, Lowers Price Target to $16
Jefferies Remains a Buy on InMode (INMD)
InMode Analyst Ratings
UBS Adjusts Price Target on InMode to $20 From $26, Maintains Neutral Rating
Needham: Reiterates that InMode (INMD.US) holds the rating.
InMode Analyst Ratings
Analysts Conflicted on These Healthcare Names: InMode (INMD) and Pfizer (PFE)